Prévention de la maladie thromboembolique veineuse, chirurgie ambulatoire et nouveaux anticoagulants oraux directs

Ambulatory surgery is associated with a very low incidence of thromboembolic events. New oral direct anticoagulants (NOAC) have been launched for thromboprophylaxis exclusively for total hip and knee replacement. Their use in ambulatory surgery is consequently not recommended so far. In patients taking NOAC, treatment must be interrupted 3 (xabans) or at least 4 (dabigatran) days before surgery and start again after 48 to 72 hours.